Neowise Biotechnology Co., Ltd, a T cell receptor (TCR)-therapy developer based in Suzhou, reportedly raised close to RMB 200 million (USD 29 million) in a Series A+ financing round. This investment will support the company’s ongoing research and development efforts in TCR therapies.
Investor Participation
The financing round was led by Oriza Seed, Marathon Venture Partners, GEM Co., Ltd., Orange Land Capital, Zhongxin Capital, and Leader Venture Capital, with additional support from existing investor TF Capital. This diverse group of investors highlights the confidence in Neowise Bio’s potential to advance innovative TCR therapies.
Company Overview
Founded in 2020, Neowise Bio has established itself as an industry leader with its TCR discovery platform. The platform is designed to identify and develop T cell receptors that can target specific cancer cells, offering a promising approach to cancer immunotherapy.
Significance of the Funding
The Series A+ funding will enable Neowise Bio to accelerate its research and development initiatives, expand its product pipeline, and enhance its capabilities in bringing innovative TCR therapies to market. This investment underscores the growing interest and potential in T cell receptor-based treatments.-Fineline Info & Tech
